SI 006
Alternative Names: SI-006Latest Information Update: 24 Aug 2023
At a glance
- Originator Shanghai Pharmaceuticals Holding
- Class Irritable bowel syndrome therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Irritable bowel syndrome
Most Recent Events
- 24 Aug 2023 Phase-II clinical trials in Irritable bowel syndrome in Canada (unspecified route), prior to August 2023 (Shanghai Pharmaceuticals Holding pipeline, August 2023)
- 24 Aug 2023 Phase-II clinical trials in Irritable bowel syndrome in USA (unspecified route), prior to August 2023 (Shanghai Pharmaceuticals Holding pipeline, August 2023)